Q32 Bio (QTTB)
Advances bempikibart, an anti-IL-7Rα antibody, for alopecia areata.
$13.80
Pre-market+0.25 (+1.85%)
At close$13.55(−5.64%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions53 holders · as of Mar 31, 2026 | 31.67% | 9.43M shares | |
| Insiders5 holders · as of Aug 27, 2026 | 2.35% | 700.5K shares | |
| Strategic holders1 holder · as of Jun 8, 2026 | 2.10% | 625.0K shares | |
| Otherremainder | 63.88% | 19.02M shares |
29.77M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Institutions13F, as of Mar 31, 2026
53 holders · 9.43M shares · 12 new positions · 26 increased · 8 reduced · 10 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Orbimed Advisors LLC | 2.25M | 7.57% | 0 | May 15, 2026 |
| Atlas Venture Life Science Advisors, LLC | 2.09M | 7.03% | 0 | May 14, 2026 |
| Opaleye Management Inc. | 1.26M | 4.22% | +1.04M | May 15, 2026 |
| Carlyle Group Inc. | 1.10M | 3.70% | 0 | May 8, 2026 |
| Arch Venture Management, LLC | 320.5K | 1.08% | 0 | May 15, 2026 |
| Acorn Capital Advisors, LLC | 315.1K | 1.06% | −178.4K | May 15, 2026 |
| Vanguard Capital Management LLC | 306.4K | 1.03% | +306.4Knew | May 15, 2026 |
| Mackenzie Financial Corp | 246.3K | 0.83% | +246.3Knew | May 13, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Orbimed Advisors LLCincl. Orbimed Capital GP Vii LLC, OrbiMed Genesis GP LLC | 13.90% | 4.13M | 13D | Jul 20, 2026 ↗ |
| Boxer Capital Management, LLC | 13.30% | 3.15M | 13G | Jul 10, 2026 ↗ |
| Sirenia Capital Management LP | 9.90% | 2.06M | 13G | May 15, 2026 ↗ |
| RA Capital Management, L.P. | 9.80% | 2.33M | 13G | Jun 4, 2026 ↗ |
| Opaleye Management Inc. | 8.59% | 1.26M | 13G | May 6, 2026 ↗ |
| Bristol-Myers Squibb Company | 6.23% | 759.1K | 13G | Nov 13, 2024 ↗ |
| Point72 Asset Management, L.P. | 5.70% | 958.8K | 13G | May 15, 2026 ↗ |
| Biotechnology Value Fund L P | 5.30% | 1.25M | 13G | Jun 4, 2026 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 25, 2026 | Shelia M. Violetteofficer: Chief Scientific Officer | Sale | 2,798 | $16.56 | 127,771 |
| Aug 25, 2026 | Lee Kalowskiofficer: CFO and President | Sale | 3,972 | $16.56 | 138,471 |
| Aug 25, 2026 | Jodie Pope Morrisondirector, officer: CEO | Sale | 9,845 | $16.56 | 343,259 |
| May 28, 2026 | Orbimed Advisors LLCdirector, 10 percent owner: | Purchase · 2 lots | 1,875,000 | $8.00 | 3,502,987 |
| May 28, 2026 | Diyong Xudirector, 10 percent owner: | Purchase · 2 lots | 1,875,000 | $8.00 | 3,502,987 |
| Feb 25, 2026 | Shelia M. Violetteofficer: Chief Scientific Officer | Sale | 2,815 | $4.51 | 55,569 |
| Feb 25, 2026 | Jodie Pope Morrisondirector, officer: CEO | Sale | 9,896 | $4.51 | 89,104 |
| Feb 25, 2026 | Lee Kalowskiofficer: CFO and President | Sale | 3,995 | $4.51 | 35,943 |
| Dec 2, 2025 | Lee Kalowskiofficer: CFO and President | Sale | 9,072 | $3.46 | 39,938 |
| Dec 2, 2025 | Jodie Pope Morrisondirector, officer: CEO | Sale | 22,506 | $3.46 | 99,000 |
CongressHouse and Senate disclosures
Not reported.